ArticleBiomaterials2013
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- In Situ Engineered "Cascade-Amplified" Drug-Loaded Vesicles for Enhanced Cancer Stem Cell Therapy.Journal of extracellular vesicles · 2026Article
- Biomaterial-based vascularization strategies for enhanced treatment of peripheral arterial disease.Journal of nanobiotechnology · 2025Review
- Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment.Beilstein journal of nanotechnology · 2025Review
- Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Drug delivery and translational research · 2024Article
- The advancement of siRNA-based nanomedicine for tumor therapy.Nanomedicine (London, England) · 2024Review
- Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Research square · 2023Article
- Cationic Materials for Gene Therapy: A Look Back to the Birth and Development of 2,2-Bis-(hydroxymethyl)Propanoic Acid-Based Dendrimer Scaffolds.International journal of molecular sciences · 2023Review
- Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification.Bioengineering (Basel, Switzerland) · 2023Article
- Polymer-Based mRNA Delivery Strategies for Advanced Therapies.Advanced healthcare materials · 2023Review
- Amphiphilic Polypeptides Obtained by Post-Polymerization Modification of Poly-l-Lysine as Systems for Combined Delivery of Paclitaxel and siRNA.Pharmaceutics · 2023Article
- Recent Advances in Nanoparticle-Mediated Co-Delivery System: A Promising Strategy in Medical and Agricultural Field.International journal of molecular sciences · 2023Review
- Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment.Frontiers in pharmacology · 2023Review
- Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.Pharmaceutics · 2022Review
- Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine.Science advances · 2022Article
- Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.Pharmaceutics · 2022Article
- Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy.Pharmaceutics · 2022Review
- Dendrimers as Antiamyloid Agents.Pharmaceutics · 2022Review
- Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.Current drug metabolism · 2022Review
- Insights on prospects of nano-siRNA based approaches in treatment of Cancer.Frontiers in pharmacology · 2022Review
- New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy.Current research in pharmacology and drug discovery · 2022Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
RNA interference by small interfering RNA (siRNA) holds promise to attenuate production of specific target proteins but is challenging in practice owing to the barriers for its efficient intracellular delivery. We have synthesized a triblock co-polymeric system, poly(amidoamine) dendrimer (generation 4)-poly(ethylene glycol)-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (G(4)-D-PEG-(2K)-DOPE). G(4)-PAMAM dendrimer was utilized as a cationic source for efficient siRNA condensation; DOPE provided optimum hydrophobicity and compatible cellular interaction for enhanced cell penetration; PEG rendered flexibility to the G(4)-D for easy accessibility of siRNA for condensation; PEG-DOPE system provided stable micellization in a mixed micellar system. G(4)-D-PEG-(2K)-DOPE was incorporated into the self-assembled PEG-(5K)-PE micelles at a 1:1 molar ratio. Our results demonstrate that the modified dendrimer, G(4)-D-PEG-(2K)-DOPE and the micellar nanocarrier form stable polyplexes with siRNA, shows excellent serum stability and a significantly higher cellular uptake of siRNA that results in target protein down-regulation when compared to the G(4)-PAMAM dendrimer. Moreover, the mixed micellar system showed efficient micellization and higher drug (doxorubicin) loading efficiency. The G(4)-D-PEG-(2K)-DOPE has the higher efficacy for siRNA delivery, whereas G(4)-D-PEG-(2K)-DOPE/PEG-(5K)-PE micelles appear to be a promising carrier for drug/siRNA co-delivery, especially useful for the treatment of multi-drug resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.